{"id":29697,"date":"2024-09-16T07:35:00","date_gmt":"2024-09-16T07:35:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4506965_CN06965_0"},"modified":"2024-09-16T07:35:00","modified_gmt":"2024-09-16T07:35:00","slug":"akesos-ivonescimab-plus-chemo-in-first-line-triple-negative-breast-cancer-showed-promising-preliminary-efficacy-and-good-safety-at-esmo-2024","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=29697","title":{"rendered":"Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024"},"content":{"rendered":"
\n

HONG KONG<\/span><\/span>, Sept. 16, 2024<\/span><\/span> \/PRNewswire\/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK<\/span>) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up, revealed that the ivonescimab combination regimen demonstrated excellent efficacy and a favorable safety profile in 1L TNBC. Professor Wang Xiaojia from Zhejiang Provincial Cancer Hospital, a co-primary investigator of the study, presented the findings orally at the conference.<\/p>\n

As of May 31, 2024<\/span>, a total of 30 patients with locally advanced unresectable or metastatic TNBC were enrolled. 80% of patients had a PD-L1 combined positive score (CPS) <10, and 60% of patients had previously received taxane-based neoadjuvant or adjuvant therapy (a proportion higher than that observed in similar studies involving targeted drugs).<\/p>\n

Although the follow-up period is relatively short and the data are not yet mature, the study still demonstrates that the ivonescimab combination regimen demonstrates excellent progression-free survival (PFS) benefits for TNBC patients, with safety consistent with previous<\/b> ivonescimab<\/b>-related studies.<\/b><\/p>\n